We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Establishing a Southern Swedish Malignant Melanoma OMICS and Biobank Clinical Capability
News

Establishing a Southern Swedish Malignant Melanoma OMICS and Biobank Clinical Capability

Establishing a Southern Swedish Malignant Melanoma OMICS and Biobank Clinical Capability
News

Establishing a Southern Swedish Malignant Melanoma OMICS and Biobank Clinical Capability

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Establishing a Southern Swedish Malignant Melanoma OMICS and Biobank Clinical Capability"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Background
The objectives and goals of the Southern Swedish Malignant Melanoma (SSMM) are to develop, build and utilize cutting edge biobanks and OMICS platforms to better understand disease pathology and drug mechanisms. The SSMM research team is a truly cross-functional group with members from oncology, surgery, bioinformatics, proteomics, and genomics initiatives. Within the research team there are members who daily diagnose patients with suspect melanomas, do follow-ups on malignant melanoma patients and remove primary or metastatic lesions by surgery. This inter-disciplinary clinical patient care ensures a competence build as well as a best practice procedure where the patient benefits.

This article was published online in Clinical and Translational Medicine, and is free to access.

Advertisement